Estudios importantes sobre hipertension arterial de Cuba y el mundo

Hypertension, not essential: an epidemic preventable by improved eating patterns

Por: J Stamler.  Journal of Human Hypertension (2013) 27, 581–582.

In most populations worldwide, blood pressure (BP) rises substantially with age from youth through middle age. The consequence is that adverse BP levels—prehypertensive and hypertensive—are epidemic, as are their adverse effects: morbidity, disability and premature death from major cardiovascular diseases (CVD; coronary heart disease, stroke, congestive heart failure and so on).
For decades, most persons with high BP were diagnosed as having essential hypertension.The word essential in front of hypertension served physicians as a tidy way to signify ignorance of the causes of adverse BP, and to justify—in the era before effective antihypertensive medications—‘watchful waiting’ and ‘judicious neglect’.
[Actualizado: 30 de septiembre 2013]

Relationships between metrics of visit-to-visit variability of blood pressure

Por: E B Levitan, N Kacirot2, S Oparil, S Julius y P Muntner.  Journal of Human Hypertension (2013) 27, 589–593.

This paper examines relationships between metrics of visit-to-visit variability (VVV) of blood pressure (BP) to determine which metrics should be calculated in studies of the association of VVV with health outcomes.

We examined correlation and agreement between quintiles for standard deviation (s.d.), standard deviation independent of the mean (SDIM), coefficient of variation (CV), successive variation (SV), average real variability (ARV), range, maximum, peak size and trough size of systolic BP in the Trial of Preventing Hypertension placebo arm (n=288). The average age of participants was 48 years. Mean systolic BP was 133.5 mm Hg.  VVV metrics were all significantly correlated (P<0.001).
[Actualizado: 30 de septiembre 2013]

Comprehensive Approach to Lower Blood Pressure (CALM-BP): a randomized controlled trial of a multifactorial lifestyle intervention

Por: A Ziv1, O Vogel, D Keret, S Pintov, E Bodenstein, K Wolkomir, K Doenyas, Y Mirovski y S Efrati.  Journal of Human Hypertension (2013) 27, 594–600.

Complementary medicine advocates the use of a multifactorial approach to address the varied aspects of hypertension. The aim of this study was to compare the blood pressure (BP) effect and medication use of a novel Comprehensive Approach to Lowering Measured Blood Pressure (CALM-BP), based on complementary medicine principles, with the standard recommended Dietary Approach to Stop Hypertension (DASH). A total of 113 patients treated with antihypertensive drugs were randomly assigned to either CALM-BP treatment (consisting of rice diet, walks, yoga, relaxation and stress management) or to a DASH+exercise control group (consisting of DASH and walks).
[Actualizado: 30 de septiembre 2013]

Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis

Por: T Funakoshi, A Latif y M D Galsky.  Journal of Human Hypertension (2013) 27, 601–611.

Sorafenib, a multi-kinase inhibitor, has been reported to be associated with hypertension (HTN). However, the risk of severe HTN with sorafenib treatment has not been well described. We performed an up-to-date meta

-analysis of high-grade HTN in cancer patients treated with sorafenib. Medline databases and the American Society of Clinical Oncology online database of meeting abstracts were searched up to August 2012 for

relevant clinical trials. Eligible studies included phase II and III trials of sorafenib in patients with any type of cancer describing events of HTN according to the Common Terminology Criteria for Adverse Events. The summary incidence, relative risk (RR), and 95% confidence intervals (CIs) were calculated.
[Actualizado: 30 de septiembre 2013]

Debe tener internet para ver la noticia de su sitio original

Una polipíldora contra el colesterol y la hipertensión

Cuatro fármacos en uno para tratar el colesterol y la hipertensión. Una polipíldora que combina tres medicamentos para regular la tensión y estatinas para bajar el colesterol ha mostrado sus primeros resultados positivos. Los estudios de investigadores británicos de la Universidad de Londres, que han analizado los efectos del fármaco en un grupo de mayores de 50 años sin problemas cardiovasculares conocidos, muestran que esta polipíldora podría ser eficaz para prevenir miles de infartos y accidentes cardiovasculares. La idea sigue la estela de otras píldoras que combinan fármacos, como las combinaciones de antibióticos o los cócteles antivirales.

Los 84 participantes en el ensayo, realizado en el Hospital Queen Mary de Londres, mostraron una reducción del 12% en la presión arterial y del 39% del colesterol dañino; niveles, según los investigadores “más propios de una persona de 20 años”. Si la mitad de los ciudadanos mayores de 50 años de Reino Unido tomaran a diario el fármaco, afirman los autores del estudio —publicado en PLoS One— se podrían prevenir 94.000 ataques y accidentes vasculares cada año.

Sin embargo, la idea de una polipíldora preventiva para una población a priori sana no satisface a otros que creen que un fármaco no puede sustituir otras medidas, como la adopción de una vida más sana a través de ejercicio físico y una dieta saludable.

(Fuente: elpais.com)  [Actualizado: 30 de sptiembre 2013].